Description
The 14-3-3η JOINTstat test may be used as an aid in the diagnosis of patients with Rheumatoid Arthritis. Augurex plans to commercialize 14-3-3η tests and reagents in Germany to expand our commercial reach.
Amendment chain · 2 entries
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $14,000 at start, $23,900 after amendment #1 (+$9,900).
- #02018-05-02$14,000
- #12018-10-17$23,900+$9,900
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2018-05-02(start date) | $14,000 | — | The 14-3-3η JOINTstat test may be used as an aid in the diagnosis of patients with Rheumatoid Arthritis. Augur… |
| #1 amendment | 2018-10-17 | $23,900 | +$9,900 | The 14-3-3η JOINTstat test may be used as an aid in the diagnosis of patients with Rheumatoid Arthritis. Augur… |
Related records · 10
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (business number 829919521)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 172-2025-2026-Q4-1040613 | National Research Council Canada | Conseil national de recherches Canada · CanExport | $28,000 | FY2027 |
| GC-WD-DEO-2023-2024-Q4-61 | Pacific Economic Development Canada | Développement économique Canada pour le Pacifique · Regional Economic Growth through Innovation | $5,000,000 | FY2024 |
| GC-WD-DEO-2021-2022-Q4-241 | Pacific Economic Development Canada | Développement économique Canada pour le Pacifique · Regional Economic Growth through Innovation | $473,500 | FY2022 |
| 172-2019-2020-Q1-928230 | National Research Council Canada | Conseil national de recherches Canada · CanExport | $27,000 | FY2020 |
| 172-2018-2019-Q1-872369 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms | $49,999 | FY2017 |
Other recipients funded under "CanExport" by National Research Council Canada | Conseil national de recherches Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 172-2026-2027-Q1-1044054 | Response Biomedical Corp. | FY2027 | $19,120 | FY2027 |
| 172-2026-2027-Q1-1043922 | Optii Corporation | FY2027 | $10,433 | FY2027 |
| 172-2026-2027-Q1-1044221 | M2M TECH INC. | FY2027 | $7,834 | FY2027 |
| 172-2026-2027-Q1-1044158 | Titan Clean Energy Projects Corporation | FY2027 | $3,600 | FY2027 |
| 172-2026-2027-Q1-1044096 | SPARC GLOBAL SOLUTIONS INC. | FY2027 | $8,549 | FY2027 |
Cite as: Glassbox record view · Federal grants & contributions · 172-2018-2019-Q1-907187 · retrieved 2026-11-14.